ChromaDex Reports 2015 Record Revenue as Ingredient Sales Grew 83%
Mar 17, 2016 20:44 pm UTC| Business
- Company Expects to Report Record Revenue for Q1 2016 - - Led by NIAGEN®, Company Expects Strong Revenue Growth in 2016 -IRVINE, Calif., March 17, 2016 -- ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary...
Mar 17, 2016 20:30 pm UTC| Business
MALVERN, Pa., March 17, 2016 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, will release its fourth quarter and full year 2015 financial results after the market close on...
Skyharbour Announces Andreas Norlin Joins Advisory Board
Mar 17, 2016 20:30 pm UTC| Business
VANCOUVER, British Columbia, March 17, 2016 -- Skyharbour Resources Ltd. (TSX-V:SYH) (OTC Grey:SYHBF) (Frankfurt:SC1N) (the “Company”) is pleased to announce the addition of Mr. Andreas Norlin as a member of the...
Perceptron Issues Statement on Shareholder Filing
Mar 17, 2016 20:20 pm UTC| Business
PLYMOUTH, Mich., March 17, 2016 -- Perceptron, Inc. (NASDAQ:PRCP), a global leader in advanced metrology technology, today issued the following statement in response to the 13-D/A filed by Moab Capital Partners on March...
Amedica Corporation Reports Fourth Quarter and Full Year 2015 Financial Results
Mar 17, 2016 20:15 pm UTC| Business
2015 Revenue of $19.5 Million at High End of Guidance Operational Cash Burn Decreases by 38% SALT LAKE CITY, March 17, 2016 -- Amedica Corporation(Nasdaq:AMDA), a company that develops and commercializes silicon...
Relypsa Announces New Employment Inducement Grants
Mar 17, 2016 20:15 pm UTC| Business
REDWOOD CITY, Calif., March 17, 2016 -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on Mar. 15, 2016, the compensation committee of the company’s board of directors granted 4 new...
Carbylan Therapeutics Engages Wedbush PacGrow to Advise on Strategic Alternatives
Mar 17, 2016 20:15 pm UTC| Business
PALO ALTO, Calif., March 17, 2016 -- Carbylan Therapeutics (NASDAQ:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies, today announced that it has engaged...